NEW YORK, April 15 - PerkinElmer said today that it has entered a research collaboration with the Rush Alzheimer's Disease Center and the Buck Institute for Age Research to identify protein and gene targets involved in the onset and progression of Alzheimer's disease.
Â
The Rush Alzheimer's Disease Center will supply brain tissue samples from patients who agreed to detailed annual clinical evaluations and brain donation at the time of death. The Buck Institute will perform genomic analysis on the tissue and PerkinElmer will perform proteomic studies to identify differentially expressed proteins in Alzheimer's and normal human brain tissue.
Â
PerkinElmer and the Buck Institute said they would release their findings in a paper to be submitted later this year.
Â
The proteomic analysis will be performed in PerkinElmer's Boston facility, and will involve up to 30 scientists led by Mary Lopez, director of biochemistry at PerkinElmer Life and Analytical Sciences.